Urinary metabolomic changes as a predictive biomarker of asthma exacerbation - 25/12/13
Doi : 10.1016/j.jaci.2013.11.004
Claudia Chaves Loureiro, MSc a, b 
, Iola F. Duarte, PhD c, Joana Gomes, BSc d, Joana Carrola, MSc c, António S. Barros, PhD d, Ana M. Gil, PhD c, Jean Bousquet, MD e, Ana Todo Bom, PhD b, Sílvia M. Rocha, PhD d
, Iola F. Duarte, PhD c, Joana Gomes, BSc d, Joana Carrola, MSc c, António S. Barros, PhD d, Ana M. Gil, PhD c, Jean Bousquet, MD e, Ana Todo Bom, PhD b, Sílvia M. Rocha, PhD d a Serviço de Pneumologia, Hospitais da Universidade de Coimbra, Coimbra, Portugal
b Centre of Pneumology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
c CICECO, Departamento de Química, Universidade de Aveiro, Aveiro, Portugal
d QOPNA, Departamento de Química, Universidade de Aveiro, Aveiro, Portugal
e University Hospital Hôpital Arnaud de Villeneuve, Montpellier, France, and Inserm, CESP Centre for Research in Epidemiology and Population Health, U1018, Respiratory and Environmental Epidemiology team, Villejuif, France
| Supported by the European Regional Development Fund (FEDER) through the Competitive Factors Thematic Operational Programme (COMPETE) and from the Foundation for Science and Technology (FCT), Portugal, under projects PEst-C/QUI/UI0062/2011 (Research Unit 62/94 QOPNA), Pest-C/CTM/LA0011/2011 (CICECO), PTDC/QUI-QUI/117803/2010 and PTDC/QUI-BIQ/119881/2010. |
|
| Disclosure of potential conflict of interest: J. Bousquet is a board member for Actelion, Almirall, Meda, Merck, MSD, Novartis, Sanofi Aventis, Takeda, Teva, and Uriach; is a member of the board of directors for Stallergenes; and has received lecture and travel fees from Almirall, AstraZeneca, Chiesi, GlaxoSmithKline, Meda, Merck, MSD, Novartis, OM Pharma, Sanofi Aventis, Schering-Plough, Takeda, Teva, and Uriach. T. Bom has received consultancy fees from Lab Vitoria, has received lecture fees from GlaxoSmithKline and MSD, has received payment for development of educational presentations from Thermo Scientific, and has received travel fees from Boehringer Ingelheim. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2013
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 133 - N° 1
P. 261 - janvier 2014 Retour au numéro
Article précédent
- Children with severe asthma have unique oxidative stress–associated metabolomic profiles
- Anne M. Fitzpatrick, Youngja Park, Lou Ann S. Brown, Dean P. Jones
- Unsuspected mild emphysema in nonsmoking patients with chronic asthma with persistent airway obstruction
- Arthur F. Gelb, Alfred Yamamoto, Thais Mauad, Jozef Kollin, Mark J. Schein, Jay A. Nadel
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?